These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34214412)

  • 41. Fentanyl harm reduction strategies among Latinx communities in the United States: a scoping review.
    Luna G; Dermid G; Unger JB
    Harm Reduct J; 2024 Aug; 21(1):150. PubMed ID: 39152433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opioid overdose history and awareness of naloxone in patients seeking outpatient detoxification.
    Bhardwaj SB; Cochran G; Kmiec J
    J Opioid Manag; 2019; 15(3):253-259. PubMed ID: 31343726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a "hub with many spokes" model.
    Knudsen HK; Freeman PR; Oyler DR; Oser CB; Walsh SL
    Addict Sci Clin Pract; 2023 Nov; 18(1):72. PubMed ID: 38031180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Community-led approaches to making naloxone available in public settings: Implementation experiences in the HEALing communities study.
    Starbird LE; Onuoha E; Corry G; Hotchkiss J; Benjamin SN; Hunt T; Schackman BR; El-Bassel N
    Int J Drug Policy; 2024 Jun; 128():104462. PubMed ID: 38795466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
    Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
    Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protocol for a mixed-methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) randomised control trial.
    Orkin A; Campbell D; Handford C; Hopkins S; Klaiman M; Leece P; Parsons JA; Shahin R; Strike C; Thorpe K; Sellen K; Milos G; Wright A; Charles M; Sniderman R; Morrison L;
    BMJ Open; 2019 Nov; 9(11):e029436. PubMed ID: 31722937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of an Opioid Overdose and Naloxone Distribution Training in a Pharmacist Laboratory Course.
    Kwon M; Moody AE; Thigpen J; Gauld A
    Am J Pharm Educ; 2020 Feb; 84(2):7179. PubMed ID: 32226065
    [No Abstract]   [Full Text] [Related]  

  • 48. Changes in overdose knowledge and attitudes in an incarcerated sample of people living with HIV.
    Reed M; Siegler A; Tabb LP; Momplaisir F; Krevitz D; Lankenau S
    Int J Prison Health; 2021 Nov; 17(4):560-573. PubMed ID: 34120416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.
    Bennett AS; Elliott L
    Transl Res; 2021 Aug; 234():43-57. PubMed ID: 33684591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of the take ACTION Train-the-Trainer model of opioid overdose education with naloxone distribution- who benefits?
    Dahlem CH; Scalera M; Chen B; McCabe SE; Boyd CJ
    Subst Abus; 2020; 41(4):485-492. PubMed ID: 31638875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the Overdose Education and Naloxone Distribution Program of the Baltimore Student Harm Reduction Coalition.
    Lewis DA; Park JN; Vail L; Sine M; Welsh C; Sherman SG
    Am J Public Health; 2016 Jul; 106(7):1243-6. PubMed ID: 27077351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality.
    Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC
    Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The optimization of harm reduction services in Massachusetts through the use of GIS: Location-allocation analyses, 2019-2021.
    Parbs JR; Srinivasan S; Pustz J; Bayly R; Shrestha S; Lewis O; Kimmel S; Meehan T; Babakhanlou-Chase H; Stopka TJ
    Prev Med; 2024 Sep; 186():108088. PubMed ID: 39084414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal Assessment of Emergency Responders' Attitudes Toward People Who Overdose and Naloxone Following an Overdose Education Training.
    Phillips S; Budesa Z; Smith R; Wood C; Winograd R
    Subst Use Addctn J; 2024 Oct; 45(4):587-597. PubMed ID: 38600798
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addressing Fear of Negative Consequences of Overdose Response: A Qualitative Study of the Perceptions of Service Industry Workers Who Encounter an Opioid Overdose in an Urban Commercial District in Atlanta, Georgia.
    Febres-Cordero S; Thompson LM; Chalfant OS; Sherman ADF; Winiker AK; Kelly UA; Smith KM
    Workplace Health Saf; 2024 Jun; 72(6):244-252. PubMed ID: 38243156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids.
    Winhusen T; Wilder C; Lyons MS; Theobald J; Kropp F; Lewis D
    Drug Alcohol Depend; 2020 Nov; 216():108265. PubMed ID: 32919098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
    Strang J; McDonald R; Alqurshi A; Royall P; Taylor D; Forbes B
    Drug Alcohol Depend; 2016 Jun; 163():16-23. PubMed ID: 26996745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.